首页> 外文OA文献 >β2-Adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of β2-adrenoceptor stimulation
【2h】

β2-Adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of β2-adrenoceptor stimulation

机译:β2-肾上腺素受体激动剂介导的对人气道平滑肌细胞增殖的抑制:β2-肾上腺素受体刺激持续时间的重要性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Airway hyperresponsiveness in asthma has been ascribed to airway wall thickening as a result of smooth muscle proliferation and hypertrophy. We have previously shown that continuous exposure to the β2-adrenoceptor agonist, salbutamol inhibits mitogen-induced proliferation of airway smooth muscle cells. In the present study, the effects of variable durations and repeated periods of exposure to β2-adrenoceptor agonists on DNA synthesis in human cultured airway smooth muscle have been investigated to model some of the possible pharmacokinetic profiles of these agents following inhalation. DNA synthesis was measured by [3H]-thymidine incorporation.Shorter periods of exposure (up to 2.5 h) of airway smooth muscle cells to salbutamol (100 nM) commencing 30 min before thrombin (0.3 u ml−1) stimulation had no effect on the subsequent increase in [3H]-thymidine incorporation. However, inhibition by salbutamol was evident with a 4.5 h exposure and was maximal after an 8.5 h exposure. Similar patterns of results were observed when fenoterol (100 nM) was used in place of salbutamol as the β2-adrenoceptor agonist or when epidermal growth factor (300 pM) was used in place of thrombin as the mitogen. Salbutamol had no effect on thrombin-stimulated [3H]-leucine incorporation after 8.5 h of exposure, but a statistically significant effect was observed after 48 h of exposure.Experiments in which DNA synthesis was measured up to 52 h after the addition of thrombin indicated that exposure to salbutamol during the first 8 h of mitogen stimulation delayed rather than inhibited the DNA synthesis.Addition of salbutamol (100 nM) at different times either before or up to 24 h after the addition of thrombin indicated that [3H]-thymidine incorporation (measured between 24 and 28 h after thrombin) could be significantly attenuated when salbutamol was added as late as 18 h after the addition of thrombin.The effects of more prolonged exposure to salbutamol were investigated by the addition of salbutamol for either 15 or 24 h per day for a total of 3 days. There were no significant differences in the level of inhibition of thrombin-stimulated [3H]-thymidine incorporation between continuous and intermittent salbutamol over the 3 day period and the inhibition was also not different to that achieved with a single continuous exposure to salbutamol over 28 h.These results indicate that although exposure to β2-adrenoceptor agonists during the first 8 h of mitogen stimulation does not have a sustained inhibitory effect on DNA synthesis, repeated intermittent or prolonged continuous exposures to salbutamol do inhibit DNA synthesis, without evidence of marked desensitization.
机译:哮喘中的气道高反应性归因于平滑肌增殖和肥大的气道壁增厚。先前我们已经表明,持续暴露于β2-肾上腺素能受体激动剂沙丁胺醇会抑制有丝分裂原诱导的气道平滑肌细胞增殖。在本研究中,已研究了持续时间和重复暴露于β2-肾上腺素能受体激动剂对人类培养的气道平滑肌DNA合成的影响,以模拟这些药物在吸入后的一些可能的药代动力学特征。 DNA的合成通过[3H]-胸苷的掺入来测量。从凝血酶(0.3 u ml-1)的刺激作用开始到30 min,呼吸道平滑肌细胞暴露于沙丁胺醇(100 nM)的最短暴露时间(最多2.5 h)对随后[3H]-胸苷掺入增加。然而,沙丁胺醇的抑制作用在暴露4.5?h时是明显的,而在暴露8.5?h后最大。当使用非诺特罗(100 nM)代替沙丁胺醇作为β2-肾上腺素受体激动剂或使用表皮生长因子(300 pM)代替凝血酶作为促分裂原时,观察到相似的结果。沙丁胺醇在8.5 h暴露后对凝血酶刺激的[3H]-亮氨酸掺入没有影响,但在48 h暴露后观察到统计学显着影响。添加凝血酶后直至52 uph的DNA合成实验表明在有丝分裂原刺激的第一个8 h期间暴露于沙丁胺醇会延迟而不是抑制DNA的合成。在添加凝血酶之前或之后的24小时内不同时间添加沙丁胺醇(100 nM)表明[3H]-胸腺嘧啶核苷的掺入(在凝血酶后24至28 h之间测得)当在添加凝血酶后18 h加入沙丁胺醇时可以显着减弱。通过在15或24 h中加入沙丁胺醇来研究更长时间暴露于沙丁胺醇的影响每天总计3天。在连续和间歇的沙丁胺醇3天期间,凝血酶刺激的[3H]-胸腺嘧啶核苷掺入的抑制水平没有显着差异,并且该抑制作用与单次连续暴露于沙丁胺醇超过28 h所获得的抑制作用也没有差异。这些结果表明,尽管在有丝分裂原刺激的最初8小时内暴露于β2-肾上腺素受体激动剂不会对DNA合成产生持续的抑制作用,但反复间歇或长期连续暴露于沙丁胺醇的确会抑制DNA合成,而没有明显的脱敏迹象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号